logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Lisinopril CAS 76547-98-3

Lisinopril CAS 76547-98-3

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 76547-98-3

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:
CAS NO::
76547-98-3
Appearance::
Solid
Molecular Formula::
C21H31N3O5
Molecular Weight::
405.488
EINECS NO::
278-488-1
MDL NO::
MFCD00214086
CAS NO::
76547-98-3
Appearance::
Solid
Molecular Formula::
C21H31N3O5
Molecular Weight::
405.488
EINECS NO::
278-488-1
MDL NO::
MFCD00214086
Lisinopril CAS 76547-98-3

Product Description:

Product Name: Lisinopril CAS NO: 76547-98-3


Synonyms:

N-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline;

L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-;

(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid;


Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.00%

Density: 1.3±0.1 g/cm3

Boiling Point: 666.4±55.0℃ at 760 mmHg

Flash Point: 356.9±31.5℃

Vapour Pressure: 0.0±2.1 mmHg at 25℃

Index of Refraction: 1.578

Storage Condition: 2-8℃

Water Solubility: H2O: ≥10 mg/mL


Safety Information:

Signal Word: Warning     

Precautionary Statements: P305+P351+P338        

Hazard Statements: H302-H319


Lisinopril is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.Target: ACELisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy [1, 2].


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.